Determination of cytomegalovirus DNA load for monitoring of cytomegalovirus disease and antiviral treatment in solid organ transplant patients, comparing limiting-dilution PCR and hybrid capture assay with cytomegalovirus isolation  Lisbeth Barkholt, Karin Loré, Gunnar Tydén, Ilona Lewensohn-Fuchs, Jan Andersson, Bo-Göran Ericzon, Göran Lundgren, Anneka Ehrnst  Clinical Microbiology and Infection  Volume 5, Issue 2, Pages 78-87 (February 1999) DOI: 10.1111/j.1469-0691.1999.tb00107.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Kinetics of the viral load using the limiting-dilution CMV PCR and the CMV hybrid capture system in four liver-transplanted patients with CMV disease. The amount of CMV DNA, using the 10-fold limiting dilution PCR (log10 curve) and the hybrid capture system (—), is presented in relation to the time after the onset of fever. Antiviral treatment, given to three patients, is marked above the curves. The relative amount of CMV DNA is indicated on the γ-axis. including a reference to the negative samples. Clinical Microbiology and Infection 1999 5, 78-87DOI: (10.1111/j.1469-0691.1999.tb00107.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 (a) The CMV DNA load, measured by the limiting-dilution PCR, in relation to the antiviral treatment in 18 courses. The treatment consisted of either intravenous ganciclovir, 10 mg/kg per day for 7-14 days, followed by intravenous maintenance therapy of 5 mg/kg per day, 5 days per week, for 2-3 weeks, or intravenous foscarnet, 60 mg/kg per day. three times daily for 2-3 weeks. The dilution factor 10−1 for CMV DNA PCR is indicated on the γ-axis. The overlapping lines have been adjusted slightly so that they can be distinguished. (b) The CMV DNA load, measured by the CMV hybrid capture system, in relation to antiviral treatment in 11 of 12 courses. The treatment consisted of ganciclovir or foscarnet. The amount of CMV genomes is given on the γ-axis. The overlapping lines have been adjusted slightly so that they can be distinguished. Clinical Microbiology and Infection 1999 5, 78-87DOI: (10.1111/j.1469-0691.1999.tb00107.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions